

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - **All Filers Are Required To Complete This Page**

1. Registrant Name:

NOVARTIS

2. Address:

701 PENNSYLVANIA AVENUE, NW, #725, WASHINGTON, DC 20004

3. Principal place of business (if different from line 2):

4. Contact Name: ANDREA MCCABE

Telephone: 2026387429

E-mail (optional): andrea.mccabe@novartis.com

Senate ID #: 9204-12

House ID #: 33589000

7. Client Name: Self

TYPE OF REPORT

8. Year 2007 Midyear (January 1 - June 30): **OR** Year End (July 1 - December 31):

9. Check if this filing amends a previously filed version of this report:

10. Check if this is a Termination Report: => Termination Date: Dec 30, 1899 11. No Lobbying Activity:

INCOME OR EXPENSES

Complete Either Line 12 **OR** Line 13

12. Lobbying Firms

INCOME relating to lobbying activities for this reporting period was:

Less than \$10,000:

\$10,000 or more: => Income (nearest \$20,000): _____

Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).

13. Organizations

EXPENSES relating to lobbying activities for this reporting period were:

Less than \$10,000:

\$10,000 or more: => Expenses (nearest \$20,000): 2,700,000.00

14. Reporting Method.

Check box to indicate expense accounting method. See instructions for description of options.

Method A. Reporting amounts using LDA definitions only

Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code

Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Registrant Name: NOVARTIS Client Name: Self

LOBBYING ACTIVITY

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: HCR (one per page)

16. Specific lobbying issues:

H.R. 3428 OTC Medicine Tax Fairness Act of 2005 S. 1514 OTC Medicine Tax Fairness Act of 2005 H.R. 5280 Distribution Act of 2006 H.R. 6111 Tax Relief and health Care Act (Medicare) S.3678 Pandemic All Hazards Preparedness Act (Biodefense) S.103 Combat Meth Act of 2005 H.R. 314 Combat Meth Act of 2005 S.950 Elimination of Neglected Diseases Act of 2005 H.R. 3057 Dept. of State, Foreign Operations, and Related Programs Appropriations Act, 2006 H.R. 2744 Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2006 Federal Food, Drug and Cosmetic Act (Section 767) H.R. 5762 Contact Lens Consumer Protection Act H.R. 5337 National Security Foreign Investment Reform and Strengthened Transparency Act of 2006 H.R. 2206 - Supplemental Appropriations H.R. 2207 - Agricultural Disaster Assistance and Western States Emergency Unfinished Business Appropriations Act of 2007 H.R. 1591 and S. 965 - US Troops Readiness, Veteran's Health, and Iraq Accountability Act of 2007 H.R. 3043 and S. 1710 - Department of Labor, Health and Human Services and Related Agencies Appropriations Act, 2008 H.R. 1908 and S. 1710 - Patent Reform Act of 2007 H.R. 1 - Implementing the 9/11 Commission Recommendations Act of 2007 S. 1082 - Prescription Drug User Fee H.R. 2900 - Food and Drug Administration Amendments Act of 2007 H.R. 3282 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2007 H.R. 3162 - Children's Health and Medicare Protection Act of 2007 Access to Life Saving Medicines Act Citizens Petition Access to Generics Public Health Service Act Drug Importation Medicare Part B and Part D Sickle Cell Anemia Immunosuppressant Legislation Gene Therapy Direct to Consumer Advertising Medicare Prescription Drugs and Modernization Act Follow-on Biologics Patent Law Reform Authorized Generics Drug Safety Legislation DoD Authorization Language Global Hypertension Best Pharmaceuticals for Children's Act Pediatric Research Equity Act H.R. 970 and S. 1378 - Dextromethorphan Distribution Act of 2007 S. 930 - Food and Drug Administration Safety Act of 2005 H.R. 2090 - Food and Drug Administration Improvement Act of 2005 S. 470 FACT Act

17. House(s) of Congress and Federal agencies contacted:

HOUSE OF REPRESENTATIVES
HOUSE OF REPRESENTATIVES
SENATE
SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: BUMBAUGH, DEBORAH
Covered Official Position (if applicable): N/A
Name: CASSERLY, DANIEL
Covered Official Position (if applicable): N/A
Name: DRAKE, DAVID
Covered Official Position (if applicable): N/A
Name: ELKIN, JAMES
Covered Official Position (if applicable): N/A
Name: GILES, THOMAS
Covered Official Position (if applicable): N/A
Name: HALLER, SARAH E.
Covered Official Position (if applicable): N/A
Name: HUGHES, GENE
Covered Official Position (if applicable): N/A
Name: SOLON, LIBBY
Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Registrant Name: NOVARTIS Client Name: Self

LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

15. General issue area code: TRD (one per page)

16. Specific lobbying issues:

China/World Trade Organization Free Trade Agreements Commerce USTR

17. House(s) of Congress and Federal agencies contacted:

U.S. Agency for International Development (USAID)

18. Name of each individual who acted as a lobbyist in this issue area:

Name: ARON, RENARD

Covered Official Position (if applicable): N/A

Name: HALLER, SARAH E.

Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above.

Novartis AG to the degree that public policies, either laws or regulations, commercially benefit Novartis Corporation, so too Novartis AG, as its parent, will benefit.

Signature: ON FILE Date: Aug 10, 2007

Printed Name and Title: ANDREA MCCABE, ADMINISTRATIVE ASSISTANT -

Registrant Name: NOVARTIS Client Name: Self

Information Update Page:

Complete ONLY where registration information has changed.

LOBBYIST UPDATE

23. Name of each previously reported individual who is NO LONGER expected to act as a lobbyist for the client

ISSUE UPDATE

24. General lobbying issues previously reported that NO LONGER pertain

AFFILIATED ORGANIZATIONS

25. Add the following organization(s)

26. Name of each previously reported organization that is NO LONGER affiliated with the registrant or client

FOREIGN ENTITIES

27. Add the following foreign entities

28. Name of each previously reported foreign entity the NO LONGER owns, OR controls, OR is affiliated with the registrant, client or affiliated organization

Signature: ON FILE Date: Aug 10, 2007

Printed Name and Title: -